Rodman & Renshaw Reiterates Market Outperform and $16 on Adventrx Pharmaceuticals

Rodman & Renshaw reiterated its Market Outperform rating on Adventrx Pharmaceuticals ANX. At the same time, the rating agency left its price target on the company's unchanged at $16. On Monday, ANX lost 15.04% of their value to finish the day at $2.09. Its shares started to rebound in today's pre-market trading, rising 1.91% to stand around $2.13.